Brief: 9 Meters Biopharma Receives Usan Approval To Use Designated Nonproprietary Name Vurolenatide For Long-Acting Glp-1 Agonist For Short Bowel Syndrome
17/05/2021 13:26
May 17 (Reuters) - 9 Meters Biopharma Inc NMTR.O :
* 9 METERS BIOPHARMA RECEIVES USAN APPROVAL TO USE
DESIGNATED
NONPROPRIETARY NAME VUROLENATIDE FOR LONG-ACTING GLP-1 AGONIST
FOR SHORT BOWEL SYNDROME
Source text for Eikon: [https://bit.ly/3tXKFlw]
Further company coverage: NMTR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on 9 Meters Biopharma
See all newsIllumina cuts annual profit forecast as biotech funding woes linger (updated)
Illumina cuts annual profit forecast
U.S. STOCKS ON THE MOVE-Pieris Pharma, Microsoft, Energy sector
U.S. STOCKS ON THE MOVE-Medtronic, Morgan Stanley, Bank of America
9 Meters Biopharma falls after filing for bankruptcy protection